List of Excipients in Branded Drug PREDNISOLONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	BENZALKONIUM CHLORIDE
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	CITRIC ACID MONOHYDRATE
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	EDETATE DISODIUM
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	GLYCERIN

Generic Drugs Containing PREDNISOLONE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	prednisolone	0121-0885	ALCOHOL
PAI Holdings LLC dba PAI Pharma	prednisolone	0121-0885	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	prednisolone	0121-0885	BENZOIC ACID
PAI Holdings LLC dba PAI Pharma	prednisolone	0121-0885	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in PREDNISOLONE?

# Of NDCs	Excipient
20	ALCOHOL
15	ANHYDROUS CITRIC ACID
4	ANHYDROUS LACTOSE
23	BENZOIC ACID

Prednisolone Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Prednisolone is a mature corticosteroid with limited composition-of-matter protection and extensive generic competition. Commercial opportunity is concentrated in differentiated formulations rather than the active ingredient itself. The strongest strategies are pediatric taste-masked liquids, preservative-free ophthalmic products, high-performance suspensions, unit-dose packaging, and formulations that improve administration, stability, or supply reliability.

Prednisolone is marketed in several chemically and technically distinct forms:

• Prednisolone base, used primarily in solid oral products.
• Prednisolone sodium phosphate, a water-soluble prodrug used in oral and ophthalmic solutions.
• Prednisolone acetate, a poorly water-soluble ester used in ophthalmic suspensions.
• Prednisolone sodium metasulfobenzoate, used in selected oral liquid products.

The excipient strategy must match the salt or ester, dosage form, target population, route of administration, and regulatory pathway.

What prednisolone formulations are commercially available?

Prednisolone products are available as oral tablets, oral solutions, oral suspensions, orally disintegrating tablets, ophthalmic suspensions, and ophthalmic solutions. The U.S. market contains multiple generic suppliers and long-established branded or legacy products.

Dosage form	Common active form	Typical strength	Primary formulation issue
Oral tablet	Prednisolone	5 mg, 10 mg, 20 mg, 50 mg	Dose flexibility, swallowing, tablet robustness
Oral solution	Prednisolone sodium phosphate	15 mg/5 mL or similar	Taste, preservative system, chemical stability
Oral suspension	Prednisolone or salt form	Product-specific	Sedimentation, redispersibility, dose uniformity
Orally disintegrating tablet	Prednisolone sodium phosphate	Product-specific	Fast disintegration, taste, moisture protection
Ophthalmic suspension	Prednisolone acetate	0.5% or 1%	Particle size, settling, ocular comfort, sterility
Ophthalmic solution	Prednisolone sodium phosphate	0.5% or 1%	Solubility, pH, sterility, ocular tolerability
Unit-dose ophthalmic product	Prednisolone acetate or sodium phosphate	Product-specific	Preservative-free stability and container compatibility

FDA labeling identifies prednisolone sodium phosphate oral solutions, prednisolone acetate ophthalmic suspensions, and prednisolone sodium phosphate ophthalmic solutions among approved dosage forms (FDA, 2024a; DailyMed, 2024a, 2024b).

Which excipients are most important in oral prednisolone products?

The highest-value oral excipient functions are taste masking, pH control, antimicrobial preservation, viscosity adjustment, solubilization, and dose-uniformity control.

Taste masking and pediatric acceptability

Prednisolone is strongly bitter. This is a material commercial barrier because oral corticosteroids are frequently prescribed to children, including for asthma exacerbations, croup, allergic reactions, and inflammatory disorders.

Common taste-masking approaches include:

• Sweeteners such as sucrose, sorbitol, xylitol, or sucralose.
• Flavors such as cherry, grape, berry, or bubblegum.
• Polyols that increase mouthfeel and reduce immediate bitterness.
• Ion-exchange resins or polymeric taste-masking systems.
• Cyclodextrins or other complexing agents where compatible with the active form.
• Coated multiparticulates or taste-masked granules for reconstitution.

Simple sweetening is often insufficient. A commercially differentiated product should control the initial bitter burst and the aftertaste while preserving chemical stability. Resin-based or polymer-based taste masking can create regulatory and manufacturing complexity but may support a stronger product position than flavor-only reformulation.

pH control and chemical stability

Prednisolone sodium phosphate is water soluble and is generally suited to clear oral solutions. Buffer selection affects:

• Active degradation.
• Preservative efficacy.
• Flavor performance.
• Container compatibility.
• Patient tolerability.
• Dose uniformity over the labeled shelf life.

Phosphate, citrate, and related buffer systems may be evaluated depending on the target pH and stability profile. Excessive buffering can increase osmolality and reduce palatability. A formulation should use the lowest buffer capacity that maintains the required stability range.

Preservatives

Multidose oral liquids commonly require antimicrobial protection. Potential preservative systems include sodium benzoate, benzoic acid, parabens, potassium sorbate, or combinations selected for the product’s pH.

The preservative system must be evaluated against:

• Antimicrobial effectiveness testing.
• Pediatric exposure limits.
• Compatibility with flavors and sweeteners.
• Sorption to plastic containers.
• Container-closure integrity.
• Regulatory precedent in the target market.

Preservatives create a meaningful differentiation opportunity in pediatric products. A preservative-free product can command a premium in selected channels, but it requires stronger microbiological controls, unit-dose packaging, or a demonstrated multidose delivery system.

Rheology and suspension control

Prednisolone base and prednisolone acetate are poorly soluble relative to the sodium phosphate form. Suspensions require controlled particle size, wetting, dispersion, sedimentation, and redispersion.

Useful excipient classes include:

• Suspending agents such as xanthan gum, cellulose derivatives, carbomers, or silica systems.
• Wetting agents such as polysorbates or poloxamers.
• Flocculating agents where a controlled flocculated system improves redispersibility.
• Density and viscosity modifiers.
• Antimicrobial preservatives.
• Buffers and tonicity agents.

The critical quality attributes are sedimentation volume, redispersibility, particle-size distribution, dose uniformity after shaking, viscosity, and pourability. Excessive viscosity can improve suspension stability but make the product difficult to pour or measure. Poor redispersion can create underdosing at the beginning of the bottle and overdosing later.

What excipients are most important in prednisolone ophthalmic products?

Ophthalmic products require a tighter control strategy than oral products because they must meet sterility, particulate, ocular tolerability, and container-closure requirements.

Prednisolone acetate ophthalmic suspension

Prednisolone acetate is poorly soluble and is commonly formulated as a micronized suspension. The commercial formulation challenge is to maintain a uniform dose while allowing the particles to reach the ocular surface without causing discomfort or blurred vision beyond the expected level.

Key excipient functions include:

• Wetting of prednisolone acetate particles.
• Control of particle growth during storage.
• Suspension stability.
• Controlled flocculation or deflocculation.
• pH adjustment.
• Tonicity adjustment.
• Antimicrobial preservation.
• Ocular comfort.

Particle size is a central differentiator. Smaller particles can improve ocular comfort and reduce grittiness, but excessive milling can alter surface energy, increase aggregation, or complicate sterile processing. A robust product should demonstrate consistent particle-size distribution, minimal crystal growth, rapid redispersion, and dose uniformity throughout the bottle.

Prednisolone sodium phosphate ophthalmic solution

The sodium phosphate form permits a clear or substantially clear ophthalmic solution. The primary formulation risks shift from suspension control to:

• Chemical degradation.
• pH drift.
• Osmolality.
• Preservative efficacy.
• Ocular irritation.
• Container interaction.
• Sterility maintenance.

A clear solution can provide a better user experience than a suspension because it does not require shaking and has less visible settling. Its commercial advantage is strongest where adherence, convenience, or postoperative use is important.

Preservative-free ophthalmic products

Preservative-free prednisolone products are a substantial lifecycle opportunity for patients with ocular-surface disease, chronic use, contact-lens restrictions, or preservative sensitivity.

Delivery options include:

• Single-dose blow-fill-seal ampoules.
• Multidose preservative-free systems with one-way valves.
• Sterile unit-dose droppers.
• Container systems designed to prevent microbial ingress.

The principal barriers are packaging cost, fill-finish complexity, extractables and leachables, dose delivery, and stability after opening. A preservative-free product may be commercially viable even without patent exclusivity if it secures hospital, ophthalmology, or specialty-pharmacy adoption.

What formulation patents could protect a prednisolone product?

A new prednisolone formulation is unlikely to obtain meaningful protection from the active ingredient alone. Patent value is more likely to come from a narrow, technically defensible formulation or delivery system.

Potential claim categories include:

Patent category	Potential protected subject matter
Oral liquid	Taste-masking matrix, pH range, preservative combination, stability profile
Oral suspension	Particle-size distribution, rheology, redispersibility, dose uniformity
Ophthalmic suspension	Micronized particle engineering, wetting system, crystal-growth control
Ophthalmic solution	Stabilized sodium phosphate solution, pH and osmolality range
Preservative-free delivery	Multidose valve, unit-dose container, microbial ingress control
Pediatric product	Palatable formulation, low-sugar or sugar-free system, dose-delivery device
Manufacturing	Sterile milling, aseptic suspension process, controlled particle-size method
Packaging	Light-protective bottle, low-sorption container, child-resistant dose system
Method of use	Dosing regimens or patient populations, subject to patentability and eligibility

Formulation claims are strongest when the composition is tied to measurable performance, such as extended stability, reduced particle growth, improved redispersibility, lower bitterness, or a specified delivery profile. Broad claims covering familiar excipient classes are more vulnerable to prior-art challenges.

When does prednisolone lose exclusivity?

Prednisolone is a legacy small-molecule corticosteroid. Basic active-ingredient exclusivity has expired in the United States and other major markets. Generic competition is established across oral and ophthalmic dosage forms.

The commercial exclusivity profile is therefore product-specific:

• New chemical entity exclusivity is not relevant to standard prednisolone products.
• Patent-term extension is generally not relevant to the original molecule.
• Product-specific formulation or delivery patents may remain relevant for newer products.
• Pediatric exclusivity may have applied to individual products or indications but does not restore broad molecule-level exclusivity.
• Regulatory exclusivity depends on the specific application and formulation.

The FDA Orange Book remains the controlling public source for listed patents and regulatory exclusivity for approved small-molecule products. Patent listings can differ by product, dosage form, strength, and applicant, and they must be reviewed at the individual product level (FDA, 2024b).

What is the Orange Book status of prednisolone?

Prednisolone has multiple approved products and abbreviated new drug applications. The practical Orange Book issue is not whether prednisolone as a molecule is protected. It is whether a particular reference-listed drug has active patents or exclusivity that affect a generic applicant.

For a new generic entrant, the main regulatory pathways are:

• Paragraph I certification where no relevant patent information is listed.
• Paragraph II certification where listed patents have expired.
• Paragraph III certification with launch after patent expiration.
• Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.
• Section viii statements for approved uses not covered by method-of-use patents, where applicable.

For mature prednisolone products, Paragraph II and Paragraph III pathways are more likely than molecule-level Paragraph IV litigation. Paragraph IV risk increases when the target is a differentiated ophthalmic delivery system, a protected oral formulation, or a product with recently listed device or formulation patents.

How strong is the prednisolone patent estate?

The base prednisolone patent estate is weak because the molecule and conventional dosage forms are old. The strength of a commercial product depends on its formulation and delivery claims.

Asset type	Patent strength	Commercial implication
Prednisolone tablet	Low	Price competition and manufacturing efficiency dominate
Conventional oral solution	Low to moderate	Taste and stability may support limited differentiation
Taste-masked pediatric liquid	Moderate	Potential premium if patient acceptance is documented
Prednisolone acetate suspension	Moderate for technical claims	Particle engineering and suspension performance can create barriers
Preservative-free ophthalmic product	Moderate to strong	Packaging and sterile delivery claims may delay substitution
Novel multidose container	Moderate to strong	Device and combination-product claims may add protection
Manufacturing process	Variable	Process know-how may be more valuable than broad patent claims

Trade secrets can be important in particle engineering, sterile processing, flavor systems, and container filling. They do not prevent generic substitution in the same way as an issued patent, but they can reduce manufacturing failures and improve launch reliability.

What are the best commercial opportunities for prednisolone?

Pediatric oral liquids

The largest formulation opportunity is a palatable, dose-flexible pediatric liquid. A competitive product would combine:

• Strong bitter suppression.
• Low dosing volume.
• Sugar-free or reduced-sugar options.
• A calibrated oral syringe.
• Stable multidose packaging.
• Preservative exposure appropriate for children.
• Simple storage requirements.
• Reliable supply across hospital and retail channels.

A ready-to-use product may have a commercial advantage over powders for reconstitution because it removes pharmacy preparation and caregiver error. A concentrated formulation can reduce dosing volume but requires careful safety engineering to prevent accidental overdose.

Preservative-free ophthalmic products

A preservative-free prednisolone product can target ophthalmologists, postoperative care, and patients with ocular-surface sensitivity. The strongest opportunity is a convenient unit-dose or preservative-free multidose system with:

• No shaking requirement for a solution.
• Low drop-volume variability.
• Low discard volume.
• Adequate in-use stability.
• Easy opening for elderly patients.
• Compatibility with surgical and specialty-pharmacy channels.

Improved ophthalmic suspension

A differentiated prednisolone acetate suspension can compete through better redispersion, reduced settling, smaller particle size, less visible residue, and improved comfort. These improvements must be demonstrated through comparative quality and usability data rather than marketing language alone.

Hospital and institutional packaging

Unit-dose oral syringes, tamper-evident bottles, and barcoded packaging can support hospital procurement. The value proposition is operational: fewer preparation steps, lower medication-error risk, easier inventory management, and better traceability.

Global-market formulations

Prednisolone is used globally, but excipient acceptability differs by market. A multinational strategy should address:

• Sugar restrictions.
• Paraben and benzyl-alcohol policies.
• Alcohol content.
• Pediatric excipient guidance.
• Local preservative expectations.
• Climatic stability zones.
• Different container materials.
• Country-specific registration of flavors and colors.

A formulation built around excipients with broad compendial and regulatory precedent can reduce development time across jurisdictions.

What generic entry risks exist for prednisolone?

Generic entry risk is high for conventional tablets and established oral liquids. The market has limited barriers where multiple approved suppliers already exist.

Risk is lower, but not absent, for:

• Preservative-free ophthalmic systems.
• Novel multidose containers.
• Highly differentiated taste-masked liquids.
• Products requiring specialized sterile suspension processing.
• Formulations with difficult particle-size control.
• Products dependent on a narrow excipient supply chain.

Commercial risks include price erosion, wholesaler substitution, pharmacy preference for lower-cost products, shortages of sterile ophthalmic products, and limited reimbursement for premium formulations. A new entrant should avoid competing solely on active-ingredient cost.

What FDA regulatory issues affect prednisolone excipient selection?

FDA review focuses on excipient safety, product quality, manufacturing consistency, and equivalence to the reference product where an abbreviated pathway is used.

Important considerations include:

• Inactive Ingredient Database precedent.
• Maximum daily exposure.
• Pediatric safety.
• Preservative effectiveness.
• Ophthalmic sterility assurance.
• Particulate matter.
• Container-closure integrity.
• Extractables and leachables.
• Comparative dissolution or release where relevant.
• Suspension dose uniformity.
• In-use stability.
• Device performance for oral syringes or multidose ophthalmic systems.

For a 505(b)(2) product, a formulation or delivery change can support a differentiated regulatory strategy, but the sponsor must establish the bridge to the listed drug and justify any new clinical, pharmacokinetic, local-tolerability, or usability data.

How does prednisolone compare with prednisone?

Prednisolone and prednisone compete in systemic corticosteroid treatment, but their formulation economics differ.

Factor	Prednisolone	Prednisone
Active form	Pharmacologically active corticosteroid	Converted to prednisolone in the body
Pediatric liquid opportunity	Strong	Also strong, but product availability varies
Ophthalmic opportunity	Established	Limited compared with prednisolone
Formulation complexity	High for ophthalmic suspensions and liquids	Primarily oral dosage-form complexity
Patent opportunity	Delivery and formulation	Delivery and formulation
Generic pressure	High	High
Differentiation route	Taste, sterility, suspension, preservative-free delivery	Taste, dose flexibility, modified delivery

Prednisolone has a broader ophthalmic formulation opportunity because prednisolone acetate and prednisolone sodium phosphate are established ocular active forms. Prednisone is more concentrated in oral systemic therapy.

Key Takeaways

• Prednisolone is a mature, highly genericized corticosteroid with no meaningful molecule-level exclusivity.
• The best commercial opportunities are formulation-led.
• Pediatric taste masking, low-volume dosing, sugar-free liquids, and reliable oral-syringe delivery are attractive oral strategies.
• Prednisolone acetate ophthalmic suspension requires strong control of particle size, wetting, sedimentation, and redispersion.
• Prednisolone sodium phosphate supports clear oral and ophthalmic solutions but shifts the technical focus to chemical stability, pH, osmolality, and preservation.
• Preservative-free ophthalmic delivery can support premium positioning and specialty-channel adoption.
• Patent protection is most credible for measurable formulation performance, particle engineering, sterile delivery, packaging, and manufacturing methods.
• Conventional tablets and oral liquids face high generic-entry and price-erosion risk.
• Manufacturing know-how, container systems, sterile processing, and supply reliability may be more commercially important than broad composition patents.
• Orange Book analysis must be performed for the specific reference product, dosage form, strength, and applicant because listed patents and exclusivity are product-specific.

FAQs

Can prednisolone be reformulated as a sugar-free pediatric liquid?

Yes. Sugar-free systems can use sorbitol, xylitol, glycerol, sucralose, or other sweetener combinations, but the formulation must control bitterness, osmolality, viscosity, preservative performance, and gastrointestinal tolerability.

Is prednisolone acetate suitable for an oral solution?

Generally, prednisolone acetate is poorly water soluble and is technically better suited to suspension products. A clear oral solution normally uses a more soluble form such as prednisolone sodium phosphate or requires a specialized solubilization system.

Can a preservative-free prednisolone eye drop receive patent protection?

Yes. Protection may be available for the container, multidose valve, sterile delivery system, suspension composition, particle engineering, or stability profile. Patentability depends on novelty, nonobviousness, enablement, and the prior art.

What is the most defensible premium positioning for prednisolone?

The strongest premium positions are preservative-free ophthalmic delivery, pediatric palatability, reduced dosing volume, improved suspension redispersion, and packaging that reduces administration or medication-error risk.

Does a new prednisolone excipient combination automatically require clinical trials?

No. The regulatory burden depends on the product type, route, formulation change, proposed indication, and regulatory pathway. A generic-equivalence strategy may rely primarily on pharmaceutical equivalence and bioequivalence, while a 505(b)(2) product may require additional bridging, usability, local-tolerability, or clinical evidence.

References

1. DailyMed. (2024a). Prednisolone sodium phosphate oral solution prescribing information. U.S. National Library of Medicine.
2. DailyMed. (2024b). Prednisolone acetate ophthalmic suspension prescribing information. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
5. U.S. Food and Drug Administration. (2023). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/
6. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development